Distribution Channel Segment Analysis: Hospital Pharmacies (Largest Segment) vs Retail and Specialty Pharmacies (Fastest-Growing Segment)

Hospital pharmacies led the non-alcoholic steatohepatitis treatment market with a 61.18% share in 2026, reflecting their central role in dispensing therapies associated with specialist-led diagnosis and management of complex liver conditions. Patients receiving evaluation or treatment within hospitals often require coordinated access to prescription medicines alongside physician supervision, laboratory monitoring, and other clinical services. Hospital pharmacies provide an integrated channel for managing treatment regimens and supporting appropriate medication use, particularly for patients with more advanced or closely monitored disease. Their direct connection with healthcare providers and established medication-distribution infrastructure continues to reinforce their importance.

The retail and specialty pharmacies segment is projected to grow at the fastest pace, supported by increasing demand for convenient access to specialized therapies outside hospital settings. Specialty pharmacies can provide medication-management support, patient education, adherence assistance, and coordination for complex treatment pathways, while retail locations improve accessibility for ongoing medication needs. As diagnosis and long-term management of metabolic and liver-related conditions become more integrated into broader outpatient care, patients may increasingly obtain therapies through community-based channels. Greater emphasis on continuity of treatment and convenient access is expected to strengthen the role of retail and specialty pharmacies.

Disease Stage Segment Analysis: NASH Stage F1 (Largest Segment) vs NASH Stage F0 (Fastest-Growing Segment)

The NASH stage F1 segment held the largest share of the non-alcoholic steatohepatitis treatment market, accounting for 36.84% in 2026, reflecting the importance of treatment and disease management during the early fibrosis stage. Patients at this stage represent an important population for interventions intended to limit disease progression and address underlying metabolic and liver-health concerns before more advanced fibrosis develops. Increasing awareness of liver disease and improvements in diagnostic assessment can support identification of patients at earlier stages, creating opportunities for timely clinical management. The focus on preventing progression and improving long-term liver outcomes continues to sustain demand within this segment.

NASH stage F0 is expected to be the fastest-growing disease-stage segment, driven by increasing emphasis on identifying liver disease before fibrosis has developed. Greater awareness of metabolic risk factors and the importance of early disease recognition is encouraging healthcare providers to focus more closely on patients with emerging liver abnormalities. Earlier identification can create opportunities for lifestyle intervention, monitoring, and appropriate therapeutic management aimed at preventing progression. As diagnostic awareness expands and healthcare increasingly emphasizes preventive disease management, the stage F0 population is expected to become more significant within the treatment landscape.